Pub. Date : 2019
PMID : 31360122
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 2 | Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 3 | Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 4 | Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 5 | Results: We have demonstrated for the first time that activation of p53 sensitizes chemoresistant NSCLC cells to CDDP by down-regulating EGFR signaling pathway and promoting intracellular ROS production. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 6 | Our findings suggest that CDDP-induced apoptosis in chemosensitive NSCLC cells involves p53 activation, leading to suppressed EGFR signaling and ROS production. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 7 | In contrast, in chemoresistant NSCLC, activated Akt promotes EGFR signaling by the positive feedback loop and suppresses CDDP-induced ROS production and apoptosis. | Cisplatin | epidermal growth factor receptor | Homo sapiens |